EyePoint Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:PV3B Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
19 May 25	Buy€52,404	Karen Zaderej	Individual	10,000	€5.32
15 May 25	Buy€48,678	Karen Zaderej	Individual	10,000	€4.89
21 Aug 24	Buy€35,711	Goran Ando	Individual	5,000	€7.14
20 Aug 24	Buy€18,011	Wendy DiCicco	Individual	2,567	€7.02
19 Aug 24	Buy€90,184	Karen Zaderej	Individual	12,500	€7.21
16 Aug 24	Buy€22,748	Nancy Lurker	Individual	3,173	€7.17
12 Jul 24	Sell€17,073	David Guyer	Individual	1,850	€9.23
03 Jun 24	Sell€17,499	David Guyer	Individual	1,850	€9.46

Insider Trading Volume

Insider Buying: PV3B insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of PV3B?
Owner Type	Number of Shares	Ownership Percentage
Public Companies	100,221	0.134%
Individual Insiders	670,857	0.897%
VC/PE Firms	3,572,335	4.78%
Hedge Funds	21,329,091	28.5%
Institutions	49,101,093	65.7%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 32.1%.

Top Shareholders

Top 25 shareholders own 93.99% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
12.1%	Cormorant Asset Management, LP	8,325,000	€43.3m	0%	4.03%
9.89%	Suvretta Capital Management, LLC	6,804,091	€35.4m	0.31%	1.68%
9.01%	Adage Capital Management, L.P.	6,200,000	€32.2m	7.83%	0.07%
8.32%	BlackRock, Inc.	5,722,045	€29.8m	8.34%	no data
5.99%	Franklin Resources, Inc.	4,118,789	€21.4m	0.23%	0.01%
5.94%	Federated Hermes, Inc.	4,085,580	€21.3m	10.2%	0.06%
5.57%	The Vanguard Group, Inc.	3,834,368	€19.9m	0.82%	no data
5.19%	TCG Crossover Management, LLC	3,572,335	€18.6m	0%	2.74%
4.62%	RA Capital Management, L.P.	3,181,818	€16.5m	0%	0.28%
3.32%	Citadel Advisors LLC	2,286,089	€11.9m	-7.33%	0.01%
2.32%	State Street Global Advisors, Inc.	1,593,211	€8.3m	6.81%	no data
2.32%	Geode Capital Management, LLC	1,593,030	€8.3m	3.52%	no data
2.23%	Perceptive Advisors LLC	1,537,274	€8.0m	0%	0.35%
2.16%	Goldman Sachs Group, Investment Banking and Securities Investments	1,482,896	€7.7m	-7.38%	no data
2.15%	Patient Square Capital, LP	1,481,977	€7.7m	5.08%	2.18%
1.97%	T. Rowe Price Group, Inc.	1,354,014	€7.0m	-42.4%	no data
1.7%	Essex Woodlands Management, Inc.	1,169,857	€6.1m	0%	2.33%
1.57%	Finepoint Capital LP	1,081,954	€5.6m	-2.62%	0.93%
1.53%	5AM Venture Management, LLC	1,050,000	€5.5m	0%	2.55%
1.17%	Morgan Stanley, Investment Banking and Brokerage Investments	807,807	€4.2m	16.5%	no data
1.16%	CHI Advisors LLC	797,594	€4.1m	19.5%	3.44%
1.09%	Bank of America Corporation, Asset Management Arm	750,211	€3.9m	15.8%	no data
0.92%	Northern Trust Global Investments	629,879	€3.3m	-2.06%	no data
0.91%	HSBC Global Asset Management (UK) Limited	625,140	€3.3m	143%	no data
0.86%	Nantahala Capital Management, LLC	593,091	€3.1m	-1.15%	0.26%

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/22 01:00
End of Day Share Price	2025/05/22 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

EyePoint Pharmaceuticals, Inc. is covered by 20 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Colleen Kusy	Baird
Andrew D'Silva	B. Riley Securities, Inc.
Jennifer Kim	Cantor Fitzgerald & Co.